TargetBeta
CHRM3
cholinergic receptor muscarinic 3 · also m3AChR · Cholinergic receptors muscarinic
7 programs in company-led studies act on CHRM3, from 5 companies: 1 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| trospiumrule | Bristol-Myers Squibb | phase 4 | 2118 running | CHRM2 | ChEMBL |
| trospium chloriderule | Bristol-Myers Squibb | phase 4 | 157 running | CHRM2 | ChEMBL |
| Glycopyrrolaterule | Novartis | phase 4 | 873 running | CHRM1, CHRM2, CHRM4, CHRM5 | ChEMBL |
| umeclidinium bromiderule | GlaxoSmithKline | phase 4 | 71 running | – | ChEMBL |
| Atropinerule | Laboratorios Sophia S.A de C.V. | phase 3 | 176 running | CHRM1, CHRM2 | ChEMBL |
| TQC3927 | Sino Biopharmaceutical | phase 2 | 30 running | ADRB2 | the company's pipeline |
| TQC3302 | Sino Biopharmaceutical | phase 1 | 10 running | ADRB2, NR3C1 | the company's pipeline |
Conditions their studies are in
- Pulmonary Disease, Chronic Obstructive, 5 programs
- Alzheimer Disease, 2 programs
- Asthma, 2 programs
- Mania, 2 programs
- Schizophrenia, 2 programs
- Autism Spectrum Disorder, 1 program
- Hyperhidrosis, 1 program
- Insulin Resistance, 1 program
- Myopia, 1 program
- Myopia, Degenerative, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 24, 2026trospium · Bristol-Myers Squibb · phase 4 · NCT06585787
- Dec 3, 2026trospium chloride · Bristol-Myers Squibb · phase 4 · NCT07204418
- May 31, 2027Glycopyrrolate · Novartis · phase 4 · NCT07073950
- Sep 2027Atropine · Laboratorios Sophia S.A de C.V. · phase 3 · NCT07329777
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.